Trademark: 79295828
Word
PRÉNUMBRA
Status
Registered
Status Code
700
Status Date
Tuesday, October 5, 2021
Serial Number
79295828
Registration Number
6504560
Registration Date
Tuesday, October 5, 2021
Mark Type
4000
Filing Date
Tuesday, August 11, 2020
Published for Opposition
Tuesday, July 20, 2021

Trademark Owner History
Clinuvel (UK) Ltd - Original Registrant

Classifications
5 Pharmaceuticals for the prevention and treatment of autoimmune, inflammatory and skin diseases or disorders, for the treatment of viral, metabolic, endocrine, musculoskeletal, ophthalmic, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders and for the prevention and treatment of genetic diseases and disorders; hemodynamic, vasoactive and anti-oncotic pharmaceuticals; Pharmaceutical drugs for the prevention and treatment of autoimmune, inflammatory and skin diseases or disorders, for the treatment of viral, metabolic, endocrine, musculoskeletal, ophthalmic, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders and for the prevention and treatment of genetic diseases and disorders; hemodynamic, vasoactive and anti-oncotic pharmaceutical drugs; Pharmaceutical preparations for the prevention and treatment of autoimmune, inflammatory and skin diseases or disorders, for the treatment of viral, metabolic, endocrine, musculoskeletal, ophthalmic, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, for the treatment of vascular anomalies and oedema and for the prevention and treatment of genetic diseases and disorders; hemodynamic, vasoactive and anti-oncotic pharmaceutical preparations; Pharmaceuticals used for cerebrovascular accidents in the nature of strokes; Cardiovascular drug preparations; Cardiovascular pharmaceuticals; cardiovascular pharmaceutical preparations; Cardiovascular medicinal agents for medical purposes; Cardiovascular drugs used in treating shocks; cardiovascular drugs used in myocardial infarctions; cardiovascular drugs used in treating arrhythmias; cardiovascular drugs used in angina pectoris; pharmaceutical preparations for the treatment of cardiovascular disease; cardiovascular drugs used in treating congestive heart failure (CHF); Pharmaceutical preparations, preferably based on analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide for use in treating skin and skin relating conditions and disorders; Medicated sun tanning preparations for pharmaceutical purposes, preferably based on analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; Pharmaceutical preparations for skin care; pharmaceutical preparations for treating skin disorders; Medicated dermatological preparations; Dermatological pharmaceutical substances; Dermatological pharmaceutical products, namely, preparations for treating or preventing skin disorders; Medicinal creams for the protection of the skin; Medicated skin care creams for medical use for treating or preventing skin disorders; Medicated skin care preparations for medical use; Medicated skin creams and lotions; medicated creams for application after exposure to the sun; pharmaceutical skin lotions; preparations for cleansing the skin for medical use; Chemical and biological preparations, substances, reagents and compounds for the delivery and storage of a wide range of pharmaceuticals which are preferably based on analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; Afamelanotide hormone in aqueous and gel formulations

Trademark Events
Apr 18, 2022
Final Decision Transaction Processed By Ib
Mar 24, 2022
Final Disposition Notice Sent To Ib
Mar 24, 2022
Final Disposition Processed
Jan 5, 2022
Final Disposition Notice Created, To Be Sent To Ib
Oct 5, 2021
Registered-Principal Register
Jul 20, 2021
Official Gazette Publication Confirmation E-Mailed
Jul 20, 2021
Published For Opposition
Jul 19, 2021
Notification Processed By Ib
Jun 30, 2021
Notification Of Possible Opposition Sent To Ib
Jun 30, 2021
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Jun 30, 2021
Notification Of Notice Of Publication E-Mailed
Jun 17, 2021
Approved For Pub - Principal Register
Jun 16, 2021
Teas/Email Correspondence Entered
Jun 16, 2021
Correspondence Received In Law Office
Jun 16, 2021
Teas Response To Office Action Received
Jan 11, 2021
Refusal Processed By Ib
Dec 21, 2020
Non-Final Action Mailed - Refusal Sent To Ib
Dec 21, 2020
Refusal Processed By Mpu
Dec 14, 2020
Non-Final Action (Ib Refusal) Prepared For Review
Dec 13, 2020
Non-Final Action Written
Dec 6, 2020
Assigned To Examiner
Oct 23, 2020
Application Filing Receipt Mailed
Oct 19, 2020
New Application Office Supplied Data Entered In Tram
Oct 15, 2020
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24